A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
Shanghai JMT-Bio Inc.
Shanghai JMT-Bio Inc.
AstraZeneca
Hoffmann-La Roche
Merck Sharp & Dohme LLC
BriaCell Therapeutics Corporation
AstraZeneca
Hoffmann-La Roche
Valo Therapeutics Oy
TCR2 Therapeutics
Artiva Biotherapeutics, Inc.
Merck Sharp & Dohme LLC
ImmunityBio, Inc.
BriaCell Therapeutics Corporation
GC Cell Corporation
Bristol-Myers Squibb
Acepodia Biotech, Inc.
Prestige Biopharma Limited
Hoffmann-La Roche
Spectrum Pharmaceuticals, Inc
ImmunityBio, Inc.
AryoGen Pharmed Co.
Hoffmann-La Roche
ImmunityBio, Inc.
RemeGen Co., Ltd.
Samyang Biopharmaceuticals Corporation
Palleos Healthcare GmbH
RemeGen Co., Ltd.
Genexine, Inc.
Teva Branded Pharmaceutical Products R&D, Inc.
BioEclipse Therapeutics
Gilead Sciences
Leap Therapeutics, Inc.
Hoffmann-La Roche
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics
Hoffmann-La Roche
Aileron Therapeutics, Inc.
Hoffmann-La Roche
Hoffmann-La Roche
Spectrum Pharmaceuticals, Inc
Spectrum Pharmaceuticals, Inc
Tanvex BioPharma USA, Inc.
Marker Therapeutics, Inc.
GlaxoSmithKline
BriaCell Therapeutics Corporation
AbbVie
Prescient Therapeutics, Ltd.
Merck Sharp & Dohme LLC